Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2229-2236

  Chirieac, Lucian R ^a,b   Swisher, Stephen G ^a   Correa, Arlene M ^a   Ajani, Jaffer A ^a   Komaki, Ritsuko R ^a   Rashid, Asif ^a   Hamilton, Stanley R ^a   Wu, Tsung Teh ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SIGNET RING CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 16844366541     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1840     Document Type: Article

References (41)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
2. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
3. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999;230:392-400.
4. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-83.
5. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-72.
6. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992;216:583-90.
7. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000;18:455-62.
8. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-32.
9. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York (NY): Springer; 2002. p. 91-8.
10. Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995;118:845-55.
11. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660-9.
12. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996;111:85-94.
13. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-76.
14. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990;8:119-27.
15. Ajani JA, Faust J, Yao J, et al. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology 2003;17:20-2.
16. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2003:CD001556.
17. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003;21:4009-15.
18. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003;9:251-60.
19. Leichman L, Steiger Z, Seydel HG, et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol 1984;2:75-9.
20. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987;5:622-8.
21. Ellis FH Jr, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997;113:836-46.
22. Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG. The significance of signet ring cells in infiltrating lobular carcinoma of the breast. Arch Pathol Lab Med 1995;119:64-8.
23. Kitamura H, Sumikawa T, Fukuoka H, Kanisawa M. Primary signet-ring cell carcinoma of the urinary bladder. Report of two cases with histochemical studies. Acta Pathol Jpn 1985;35:675-86.
24. Merchant SH, Amin MB, Tamboli P, et al. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-9.
25. Yamashina M. Avariant of early gastric carcinoma. Histologic and histochemical studies of early signet ring cell carcinomas discovered beneath preserved surface epithelium. Cancer 1986;58:1333-9.
26. Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer - the advent of the era of individualization. N Engl J Med 2002;347:1705-9.
27. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.
28. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
29. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.
30. Takubo K, Takai A, Yamashita K, Onda M. Carcinoma with signet ring cells of the esophagus. Acta Pathol Jpn 1987;37:989-95.
31. Rubio CA, Lagergren J. Histological features pertinent to local tumour progression in Barrett's adenocarcinoma. Anticancer Res 2003;23:3015-8.
32. Paraf F, Flejou JF, Pignon JP, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 1995;19:183-91.
33. Tung SY, Wu CS, Chen PC. Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study. Am J Gastroenterol 1996;91:2195-9.
34. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
35. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-23.
36. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
37. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
38. Fink U, Stein HJ, Bochtler H, Roder JD, Wilke HJ, Siewert JR. Neoadjuvant therapy for squamous cell esophageal carcinoma. Ann Oncol 1994;5 Suppl 3:17-26.
39. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
40. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 2004;28:215-23.
41. Hornick JL, Farraye FA, Wang HH, Odze RD. Prevalence and significance of acellular mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's associated adenocarcinoma. Mod Pathol 2003;16:121-2A.